Development of Dikang Pharmaceutical Company

The company consists of Chengdu Dikang Pharmaceutical Co., Ltd., Chongqing Dikang Changjiang Pharmaceutical Co., Ltd., Dikang Pharmaceutical Trading Branch, Sichuan Heping Pharmacy Chain Co., Ltd., Chengdu Dikang Zhongke Biomedical Materials Co., Ltd., Lhasa Dikang Pharmaceutical Technology Co., Ltd. and other subsidiaries. The company covers an area of 500 mu and has 598 kinds of products, including 0/2 national new drugs, 7 national traditional Chinese medicine protected varieties and 27 patents (1. Complete dosage forms, products all over the country. The company's main products are the national "863" frontier project "Absorbable Fracture Internal Fixation Screw", the national new drug "Ancestor" (pioglitazone hydrochloride tablets), "Arcelor" (rabeprazole sodium enteric-coated tablets) and so on. Dikang's research project "Dikang (antiviral) injection" is a new Chinese medicine, which has been included in the national "863" project and the national "Tenth Five-Year Plan". Since its establishment, Dikang Pharmaceutical has attached great importance to scientific and technological innovation and sustainable development. On the basis of focusing on the modernization and industrialization of traditional Chinese medicine and new biomedical materials, we devoted ourselves to the research and development of new biomedical materials, especially slow-release and controlled-release materials, established a technical platform with independent intellectual property rights and characteristics, and built the company into a large-scale R&D and production enterprise integrating drugs and medical devices. Dikang Pharmaceutical takes "climbing the medical peak and swearing to be the backbone of China" as its own responsibility, takes scientific and technological innovation as the guide, contributes excellent products and always serves human health.